Cargando…

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair

BACKGROUND: We evaluated the impact of 3 months of mFOLFOX6 adjuvant chemotherapy or surgery alone in comparison with 6 months of mFOLFOX6 on disease-free survival (DFS) in deficient mismatch repair (dMMR) colon cancer (CC) patients. METHODS: This retrospective study identified a cohort of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Huabin, Wu, Zehua, Wang, Chao, Huang, Yan, Zhang, Jianwei, Cai, Yue, Xie, Xiaoyu, Li, Jianxia, Shen, Cailu, Li, Weiwei, Ling, Jiayu, Xu, Xuehu, Deng, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747753/ https://www.ncbi.nlm.nih.gov/pubmed/33344234 http://dx.doi.org/10.3389/fonc.2020.579478

Ejemplares similares

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients
por: Li, Jianxia, et al.
Publicado: (2020)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

Prognostic impact of high-risk factors and KRAS mutation in patients with stage II deficient mismatch repair colon cancer: a retrospective cohort study
por: Zhang, Yuting, et al.
Publicado: (2022)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
por: Cheng, Yi, et al.
Publicado: (2022)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy
por: Wu, Zehua, et al.
Publicado: (2022)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
por: Okuno, Keisuke, et al.
Publicado: (2023)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
por: Zhang, Chunze, et al.
Publicado: (2022)

Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
por: Tomasello, Gianluca, et al.
Publicado: (2022)

Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
por: Lu, C-Y, et al.
Publicado: (2013)

Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer
por: Hestetun, Kjersti Elvestad, et al.
Publicado: (2022)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
por: Zhang, Linjie, et al.
Publicado: (2023)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis
por: Boyne, Devon J., et al.
Publicado: (2019)

Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy
por: Cha, Yoon Jin, et al.
Publicado: (2019)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
por: Kim, Seong-Geun, et al.
Publicado: (2016)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
por: Karoui, Mehdi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uqt0if9ovd6138n2aicj1ab4g7